Publication details

 

Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)

book cover

Basic information
Original title:Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)
Authors:Romana Zaoralová, Petr Kuglík, Hana Filková, Henrieta Grešliková, Pavel Němec, Alexandra Oltová, Luděk Pour, Zdeněk Adam, Andrea Křivanová, Marta Krejčí, Roman Hájek
Information from University Press
Price:Not for sale
Publisher within MU:Faculty of Medicine
Further information
Citation:ZAORALOVÁ, Romana, Petr KUGLÍK, Hana FILKOVÁ, Henrieta GREŠLIKOVÁ, Pavel NĚMEC, Alexandra OLTOVÁ, Luděk POUR, Zdeněk ADAM, Andrea KŘIVANOVÁ, Marta KREJČÍ a Roman HÁJEK. Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade). In From cell sorting to plasma cell identification and chromosomal aberrations in multiple myeloma – Application manual. Brno: vydavatelství Masarykovy Univerzity, 2007. s. 12-13, 2 s. ISBN 978-80-210-4417-3.Export BibTeX
@inproceedings{726821,
author = {Zaoralová, Romana and Kuglík, Petr and Filková, Hana and Grešliková, Henrieta and Němec, Pavel and Oltová, Alexandra and Pour, Luděk and Adam, Zdeněk and Křivanová, Andrea and Krejčí, Marta and Hájek, Roman},
address = {Brno},
booktitle = {From cell sorting to plasma cell identification and chromosomal aberrations in multiple myeloma – Application manual},
keywords = {Multiple myeloma; CKS1B amplification; RB deletion; p53 deletion; t(4;14); cIg FISH},
language = {eng},
location = {Brno},
isbn = {978-80-210-4417-3},
pages = {12-13},
publisher = {vydavatelství Masarykovy Univerzity},
title = {Clinical implications of chromosomal aberrations (13q14 and 17p13 deletion, translocation t(4;14) and 1q21 amplification) in patients with relapsed multiple myeloma treated by thalidomide or bortezomib (Velcade)},
year = {2007}
}
Original language:English
Field:Genetics and molecular biology
Type:Article in Proceedings
Keywords:Multiple myeloma; CKS1B amplification; RB deletion; p53 deletion; t(4;14); cIg FISH

The aim of the work was: 1) To study the incidence of the chromosomal aberrations known as adverse prognostic factors in MM - deletion of 13q14 (RB1), deletion of 17p13 (p53), amplification of 1q21 (CKS1B) and translocation t(4;14) in a group of 40 patients with relapsed MM. 2) To compare the prognostic and predictive significance of these unfavorable chromosomal aberrations in patients with relapsed MM treated with thalidomide or bortezomib (Velcade) based regimens.

Related projects: